Cetuximab biosimilar - Shanghai Henlius BiotechAlternative Names: Anti-EGFR monoclonal antibody 225 biosimilar - Shanghai Henlius Biotech; HLX 05
Latest Information Update: 18 Jun 2015
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 01 Dec 2014 Preclinical trials in Colorectal cancer in China (IV) before December 2014
- 01 Dec 2014 Shanghai Henlius Biotech files an IND application with the CFDA in China for Colorectal cancer